Results 21 to 30 of about 274,125 (232)

Effect of Vaginal Laser and Topical Therapies on Vulvovaginal Atrophy Symptoms in Breast Cancer Patients: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Background: Vulvovaginal atrophy (VVA) significantly impacts the quality of life in breast cancer patients leading to symptoms like vaginal dryness, dyspareunia, and genital discomfort.
Lőczi LL, Vleskó G, Éliás M, Turan C, Kajtár P, Tóth R, Sipos M, Nagy R, Hegyi P, Ács N, Várbíró S, Keszthelyi M.   +11 more
europepmc   +2 more sources

Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India. [PDF]

Cureus
Background Urogenital health is a necessary part of health for all women, especially in the postmenopausal age group. We suspected that the increased incidence of vulvovaginal atrophy (VVA) had some or other effects on the quality of life of older women.
Ulhe SC, Acharya N, Vats A, Singh A.
europepmc   +2 more sources

Vulvovaginal atrophy in women with and without a history of breast cancer: Baseline data from the PatiEnt satisfactiON studY (PEONY) in Italy [PDF]

Maturitas
Objectives: To assess clinical characteristics of postmenopausal women with moderate/severe vulvovaginal atrophy, as well as its impact on sexual function, well-being, and quality of life, and to provide an overview of most used treatments. Study design:
Becorpi A., Di Paolantonio T., Maffei S., Meriggiola M. C., Nappi R. E., Nicolucci A., Salvatore S., Villa P.   +7 more
core   +5 more sources

Vulvovaginal atrophy during menopause [PDF]

, 2017
Objective: To present a basic clinical research based on current evidence about advanced treatment methods for vulvovaginal atrophy during menopause.And on principles of management of patients with vulvovaginal atrophy.Vulvovaginal atrophy (VVA) is a ...
Orru, A.J.
core   +2 more sources

Real‑world performance and safety of vaginal ovules in reducing the vaginal symptoms associated with vulvovaginal atrophy and postmenopausal sexual dysfunction. [PDF]

Biomed Rep
Decreasing estrogen levels during the postmenopausal period results in tissue atrophy and physiological changes, such as thinning of the vaginal epithelium, prolapse and decreased pelvic floor strength and control.
Iliescu DG, Petrita R, Teodorescu C, Olaru RA, Alexa AA, Petre I.   +5 more
europepmc   +2 more sources

Effect of Vitamin D Supplement on Vulvovaginal Atrophy of the Menopause. [PDF]

Nutrients, 2020
The effects of oral vitamin D supplements on vaginal health in postmenopausal women with vulvovaginal atrophy (VVA) was evaluated. A double-blinded, randomized placebo-controlled trial was conducted for 12 weeks to investigate changes on vaginal maturation index (VMI), vaginal pH, and the visual analog scale (VAS) of VVA symptoms.
Kamronrithisorn T, Manonai J, Vallibhakara SA, Sophonsritsuk A, Vallibhakara O.   +4 more
europepmc   +4 more sources

Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy

International Journal of Women's Health, 2013
Several recent, large-scale studies have provided valuable insights into patient perspectives on postmenopausal vulvovaginal health. Symptoms of vulvovaginal atrophy, which include dryness, irritation, itching, dysuria, and dyspareunia, can adversely affect interpersonal relationships, quality of life, and sexual function.
Parish,Sharon J, Nappi,Rossella E, Krychman,Michael L, Kellogg-Spadt,Susan, Simon,James A, Goldstein,Jeffrey A, Kingsberg,Sheryl A   +6 more
openaire   +7 more sources

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy. [PDF]

J Menopausal Med, 2017
Ospemifene-a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013-is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia.
Shin JJ, Kim SK, Lee JR, Suh CS.
europepmc   +4 more sources

Should I stay for local hormone therapy or should I go for radiofrequency to treat vulvovaginal atrophy? A patient preference trial. [PDF]

Menopause
The use of quadripolar radiofrequency devices seems effective, but it is not associated with better clinical outcomes compared with topical hormone treatment.
Dell'Utri CM, Manzoni E, Bonfanti I, Marrocco F, Barbara G, Pifarotti P, Chiaffarino F.   +6 more
europepmc   +2 more sources

Update on alternative therapies for vulvovaginal atrophy

Patient Preference and Adherence, 2011
Although systemic absorption of estrogen with local treatment for vulvovaginal atrophy (VVA) is most likely to be negligible, it is unknown whether this minimal absorption will affect outcomes in women with breast cancer. Use of adjuvant therapy with aromatase inhibitors for breast cancer is associated with high incidence of VVA symptoms.
Chollet J
openaire   +6 more sources